DOCSLIB.ORG

FEAM) As a New Conditioning Regimen for Lymphoma Patients Undergoing Auto-SCT: a Multicenter Feasibility Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FEAM) As a New Conditioning Regimen for Lymphoma Patients Undergoing Auto-SCT: a Multicenter Feasibility Study Bone Marrow Transplantation (2010) 45, 1147–1153 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study M Musso1, R Scalone1, G Marcacci2, F Lanza3, N Di Renzo4, N Cascavilla5, P Di Bartolomeo6, A Crescimanno1, T Perrone7 and A Pinto2 1Department of Oncology, Oncohematology and Bone Marrow Transplantation Unit, ‘La Maddalena’, Palermo, Italy; 2Hematology- Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione ‘G Pascale’, IRCCS, Naples, Italy; 3Section of Hematology, University Hospital, St Anna Hospital, Ferrara, Italy; 4Hematology Unit, ‘Vito Fazi’ Hospital, Lecce, Italy; 5Hematology Unit and Bone Marrow Transplantation, IRCSS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo (FG), Italy; 6Department of Hematology, Bone Marrow Transplant Centre, Ospedale Civile, Pescara, Italy and 7Scientific Department, Italfarmaco S.p.A, Cinisello Balsamo (MI), Italy BEAM is a widely used conditioning regimen for Introduction relapsed/refractory lymphoma patients undergoing auto- SCT. We conducted a multicenter study with an alter- BEAM is a widely adopted conditioning regimen for native regimen (fotemustine plus etoposide, cytarabine autologous hemopoietic SCT (ASCT) in patients with and melphalan (FEAM)) in which BCNU was substituted Hodgkin’s (HL) and non-Hodgkin’s lymphoma (NHL), by the chloroethylnitrosourea fotemustine (FTM). Eighty- and has an acceptable toxicity and high efficacy.1 Adverse four patients with relapsed/refractory Hodgkin’s (n ¼ 20) events associated with carmustine-containing conditioning and non-Hodgkin’s lymphoma (n ¼ 64) were conditioned regimens (that is, BEAM, BEAC) are partly related to with a FEAM regimen (FTM 150 mg/m2 on days –7, –6, BCNU and most commonly include severe mucositis, etoposide 200 mg/m2 and cytarabine 400 mg/m2 on days chemotherapy-induced nausea and vomiting, diarrhea, –5, –4, –3, –2 and melphalan 140 mg/m2 on day –1). hepatotoxicity and nephrotoxicity.1–4 In addition, non- Patients were evaluated for toxicity and engraftment infective toxic pulmonary complications have been repor- parameters. Median times to neutrophil (4500 Â 109/l) ted in 16–64% of patients after carmustine-containing and plt (420 000 Â 109/l) engraftment were 11 and high-dose regimens.5 Post transplant lung toxicity in 13 days, respectively. Grade 3 mucositis occurred in patients receiving carmustine-based conditioning has been 19 patients (23%), while G3 nausea/vomiting and G3 related to the fact that BCNU inhibits the glutathione diarrhea were observed in 13 (15%) and 6 (7%) patients, reductase tissue detoxification system.6 As BCNU-related respectively. No severe hepatic, renal or pulmonary major pulmonary toxicity represents an invalidating and toxicity was detected. Seven patients (7%) experienced sometimes fatal complication of ASCT, accurate monitoring G4 mucositis, while no other G4 toxicities or unexpected of respiratory functions, prompt initiation of steroid therapy adverse events of any grade were recorded. Transplant- and even carmustine dose reductions, especially in BCNU related mortality was 2.4%. We conclude that a FEAM plus CY-containing regimens, have been suggested.5,7 regimen is feasible and safe. Although toxicity and Fotemustine (FTM) is a third-generation chloroethyl- engraftment times compared favorably with BEAM, nitrosourea containing a phosphoalanine carrier group longer follow-up is needed to evaluate fully its efficacy attached to the nitrosourea radical.8 The phosphoalanine and long-term safety. group makes the drug highly lipophilic, as shown by the Bone Marrow Transplantation (2010) 45, 1147–1153; octanol/water partition coefficient, which is in the optimal doi:10.1038/bmt.2009.318; published online 9 November 2009 range compared with other nitrosoureas such as BCNU Keywords: fotemustine; carmustine; FEAM; BEAM; and CCNU.9,10 This characteristic allows FTM to cross the conditioning; auto-SCT blood-brain barrier (BBB), as shown by experimental studies in animals.11,12 In addition, as FTM does not significantly alter glutathione reductase activity, a more favorable pulmonary toxicity profile for this agent can be predicted compared with BCNU.13 In fact, several clinical Correspondence: Dr M Musso, Department of Oncology, Oncohema- trials have confirmed that FTM, unlike other nitrosoureas, tology and BMT Unit ‘La Maddalena’, Via San Lorenzo Colli 312/D, shows no significant pulmonary toxicity.14–16 I-90146, Palermo, Italy. E-mail: [email protected] With regards to antitumor activity, a phase II study by 17 Received 14 April 2009; revised 17 September 2009; accepted 29 Jacquillat et al., showed that administration of a non- September 2009; published online 9 November 2009 myeloablative schedule of FTM (100 mg/m2 on days 1, 8 Fotemustine-based conditioning for autologous transplant M Musso et al 1148 and 15 (induction), followed after 4–5 weeks by a single Table 1 Dosage and schedule of the FEAM regimen 100 mg/m2 maintenance dose, every 21 days), induced Drug Dose Day objective clinical responses in 7 of 13 heavily pre-treated patients with hematologic malignancies including HL and FTM 150 mg/m2 –7, –6 NHL; thrombocytopenia was the most commonly observed Etoposide 200 mg/m2 –5, –4, –3, –2 2 toxicity. In addition, Rigal-Huguet et al.18 conducted an Ara-C 400 mg/m –5, –4, –3, –2 Melphalan 140 mg/m2 –1 intensification pilot study with autotransplantation of BM in NHL patients in which high-dose FTM was substituted Abbreviations: FEAM ¼ fotemustine plus etoposide, cytarabine and for BCNU in modified BEAM/BEAC-like regimens (FTM, melphalan; FTM ¼ fotemustine. 300 mg/m2; etoposide 500 mg/m2; cytarabine, 400 mg/m2 and melphalan 140 mg/m2 or CY 6.0 g/m2). blood progenitor cells were infused on day 0, followed The aim of this pharmacokinetic study was to show the by s.c. G-CSF (5 mg/kg) from day 1 of ASCT until passage of FTM through the BBB and the feasibility of 2 consecutive days when the ANCs were X1000 Â 109/l. increasing the dose of the drug. Prophylaxis for opportunistic infections and antimicrobial Given the comparable antitumor activity of FTM therapy in cases of febrile episodes as well as standard with respect to BCNU, in addition to a more favorable supportive measures including blood and plt transfusions safety profile, we conducted a multicenter study of a novel were administered according to the standard protocols and FTM-based high-dose regimen (fotemustine plus etoposide, policies of each participating center. Similarly, protocols cytarabine and melphalan (FEAM)) in which BCNU was for antiemetic prophylaxis used during FEAM administra- substituted by an equal dose (300 mg/m2) of FTM without tion, were identical to those currently used for BEAM at further modifications of the BEAM platform. The results, participating centers and consisted of serotonin 5-HT3- in a series of 84 consecutive patients with refractory and receptor antagonists and dexamethasone. relapsed lymphoma, show that FEAM, followed by auto- logous hemopoietic rescue with peripheral blood progeni- tor cells, is a feasible conditioning strategy associated Study definitions, safety and efficacy evaluations with a favorable toxicity profile and timely hemopoietic The primary objectives of the study were to assess the engraftment. feasibility and safety of the FEAM regimen in terms of acute toxicity and hemopoietic engraftment. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria version 3.0 (http://ctep. Patients and methods cancer.gov/protocoldevelopment/electronic_applications/docs/ ctcaev3.pdf). Transplant-related mortality (TRM) was Eligibility criteria defined as any death related to a fatal complication in the In all, 84 eligible patients with relapsed/refractory HL absence of the underlying disease within 100 days from (n ¼ 20) or NHL (n ¼ 64), were consecutively enrolled. transplantation. Secondary end points included evaluation The study was conducted according to the Declaration of of the efficacy of the FEAM regimen in terms of event free Helsinki, and all patients signed a written informed consent survival and overall survival. Disease status at transplant- form before treatment. Eligible patients were required to ation and response to high-dose chemotherapy, assessed 1 have histologically proven relapsed/refractory HL or NHL month after ASCT, were evaluated with standard response after first-line chemotherapy. High-risk patient candidates criteria for lymphoma.19 Event free survival was defined as to upfront high-dose consolidation and ASCT were also the time between ASCT and the occurrence of a serious accrued. Other eligibility criteria included a Karnofsky morbidity (that is, a life-threatening complication requiring Performance Status 460, adequate cardiac, pulmonary, hospitalization or prolonging ongoing hospitalization hepatic and renal function, and no acute or uncontrolled resulting in death or significant disability/incapacity), bacterial or viral infections before transplantation. Patients disease relapse, disease progression or death from any with uncontrolled comorbid conditions or active toxicity cause. Overall survival was defined as the time from ASCT from salvage chemotherapy were considered ineligible. until death or the date of last follow-up when the patient was known to be alive. Conditioning regimen In all of the cases
Load more

Recommended publications
  • Bevacizumab Plus Fotemustine As First-Line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors
    Published OnlineFirst October 28, 2010; DOI: 10.1158/1078-0432.CCR-10-2363 Clinical Cancer Cancer Therapy: Clinical Research Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors Michele Del Vecchio1, Roberta Mortarini2, Stefania Canova1, Lorenza Di Guardo1, Nicola Pimpinelli3, Mario R. Sertoli4, Davide Bedognetti4, Paola Queirolo5, Paola Morosini6, Tania Perrone7, Emilio Bajetta1, and Andrea Anichini2 Abstract Purpose: To assess the clinical and biological activity of the association of bevacizumab and fotemustine as first-line treatment in advanced melanoma patients. Experimental Design: Previously untreated, metastatic melanoma patients (n ¼ 20) received bevaci- zumab (at 15 mg/kg every 3 weeks) and fotemustine (100 mg/m2 by intravenous administration on days 1, 8, and 15, repeated after 4 weeks) in a multicenter, single-arm, open-label, phase II study. Primary endpoint was the best overall response rate; other endpoints were toxicity, time to progression (TTP), and overall survival (OS). Serum cytokines, angiogenesis, and lymphangiogenesis factors were monitored by multiplex arrays and by in vitro angiogenesis assays. Effects of fotemustine on melanoma cells, in vitro, on vascular endothelial growth factor (VEGF)-C release and apoptosis were assessed by ELISA and flow cytometry, respectively. Results: One complete response, 2 partial responses (PR), and 10 patients with stable disease were observed. TTP and OS were 8.3 and 20.5 months, respectively. Fourteen patients experienced adverse events of toxicity grade 3–4. Serum VEGF-A levels in evaluated patients (n ¼ 15) and overall serum proangiogenic activity were significantly inhibited. A significant reduction in VEGF-C levels was found in several post-versus pretherapy serum samples.
    [Show full text]
  • Use of Fluorescence to Guide Resection Or Biopsy of Primary Brain Tumors and Brain Metastases
    Neurosurg Focus 36 (2):E10, 2014 ©AANS, 2014 Use of fluorescence to guide resection or biopsy of primary brain tumors and brain metastases *SERGE MARBACHER, M.D., M.SC.,1,5 ELISABETH KLINGER, M.D.,2 LUCIA SCHWYZER, M.D.,1,5 INGEBORG FISCHER, M.D.,3 EDIN NEVZATI, M.D.,1 MICHAEL DIEPERS, M.D.,2,5 ULRICH ROELCKE, M.D.,4,5 ALI-REZA FATHI, M.D.,1,5 DANIEL COLUCCIA, M.D.,1,5 AND JAVIER FANDINO, M.D.1,5 Departments of 1Neurosurgery, 2Neuroradiology, 3Pathology, and 4Neurology, and 5Brain Tumor Center, Kantonsspital Aarau, Aarau, Switzerland Object. The accurate discrimination between tumor and normal tissue is crucial for determining how much to resect and therefore for the clinical outcome of patients with brain tumors. In recent years, guidance with 5-aminolev- ulinic acid (5-ALA)–induced intraoperative fluorescence has proven to be a useful surgical adjunct for gross-total resection of high-grade gliomas. The clinical utility of 5-ALA in resection of brain tumors other than glioblastomas has not yet been established. The authors assessed the frequency of positive 5-ALA fluorescence in a cohort of pa- tients with primary brain tumors and metastases. Methods. The authors conducted a single-center retrospective analysis of 531 patients with intracranial tumors treated by 5-ALA–guided resection or biopsy. They analyzed patient characteristics, preoperative and postoperative liver function test results, intraoperative tumor fluorescence, and histological data. They also screened discharge summaries for clinical adverse effects resulting from the administration of 5-ALA. Intraoperative qualitative 5-ALA fluorescence (none, mild, moderate, and strong) was documented by the surgeon and dichotomized into negative and positive fluorescence.
    [Show full text]
  • Melphalan) for Injection, for Intravenous Use History of Serious Allergic Reaction to Melphalan Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------DOSAGE FORMS AND STRENGTHS----------------------- These highlights do not include all the information needed to use For Injection: 50 mg per vial, lyophilized powder in a single-dose vial for EVOMELA safely and effectively. See full prescribing information for reconstitution. (3) EVOMELA. ---------------------------CONTRAINDICATIONS---------------------------------- EVOMELA® (melphalan) for injection, for intravenous use History of serious allergic reaction to melphalan Initial U.S. Approval: 1964 WARNING: SEVERE BONE MARROW SUPPRESSION, ---------------------WARNINGS AND PRECAUTIONS-------------------------- HYPERSENSITIVITY, and LEUKEMOGENICITY See full prescribing information for complete boxed warning. • Gastrointestinal toxicity: Nausea, vomiting, diarrhea or oral mucositis may occur; provide supportive care using antiemetic and antidiarrheal • Severe bone marrow suppression with resulting infection or medications as needed. (2.1, 5.2) bleeding may occur. Controlled trials comparing intravenous (IV) • Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to melphalan to oral melphalan have shown more myelosuppression fetus and to avoid pregnancy . (5.6, 8.1, 8.3) with the IV formulation. Monitor hematologic laboratory • Infertility: Melphalan may cause ovarian function suppression or testicular parameters. (5.1) suppression. (5.7) • Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation
    [Show full text]
  • UC Irvine UC Irvine Previously Published Works
    UC Irvine UC Irvine Previously Published Works Title ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN Permalink https://escholarship.org/uc/item/2w97d9jv Journal Neuro-Oncology, 20(suppl_6) ISSN 1522-8517 Authors Kong, Xiao-Tang Lai, Albert Carrillo, Jose A et al. Publication Date 2018-11-05 DOI 10.1093/neuonc/noy148.045 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Abstracts 3 dyspnea; grade 2 hemorrhage, non-neutropenic fever; and grade 1 hand- toxicities include: 1 patient with pre-existing vision dysfunction had Grade foot. CONCLUSIONS: Low-dose capecitabine is associated with a modest 4 optic nerve dysfunction; 2 Grade 4 hematologic events and 1 Grade 5 reduction in MDSCs and T-regs and a significant increase in CTLs. Toxicity event(sepsis) due to temozolamide-induced cytopenias. CONCLUSION: has been manageable. Four of 7 evaluable patients have reached 6 months 18F-DOPA-PET -guided dose escalation appears reasonably safe and toler- free of progression. Dose escalation continues. able in patients with high-grade glioma. ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL COMBINATION WITH STANDARD THERAPY FOR UPFRONT OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Downloaded from https://academic.oup.com/neuro-oncology/article/20/suppl_6/vi13/5153917 by University of California, Irvine user on 27 May 2021 METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN Vinay Puduvalli1, Jing Wu2, Ying Yuan3, Terri Armstrong2, Jimin Wu3, Xiao-Tang Kong1, Albert Lai2, Jose A.
    [Show full text]
  • 2016 ASCO TRC102 + Temodar Phase 1 Poster
    Phase I Trial of TRC102 (methoxyamine HCL) in Combination with Temozolomide in Patients with Relapsed Solid Tumors Robert S. Meehan1, Alice P. Chen1, Geraldine Helen O'Sullivan Coyne1, Jerry M. Collins1, Shivaani Kummar1, Larry Anderson1, Kazusa Ishii1, Jennifer Zlott1, 1 1 2 1 1 2 2 1,3 #2556 Larry Rubinstein , Yvonne Horneffer , Lamin Juwara , Woondong Jeong , Naoko Takebe , Robert J. Kinders , Ralph E. Parchment , James H. Doroshow 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892 2Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702; 3Center for Cancer Research, NCI, Bethesda, Maryland 20892 Introduction Patient Characteristics Adverse Events Response • Base excision repair (BER), one of the pathways of DNA damage repair, has been implicated in No. of Patients 34 C3D1 chemoresistance. Age (median) 60 Adverse Event Grade 2 Grade 3 Grade 4 Baseline C3D1 Baseline Range 39-78 Neutrophil count decreased 1 3 2 • TRC102 is a small molecule amine that covalently binds to abasic sites generated by BER, Race Platelet count decreased 2 1 2 resulting in DNA strand breaks and apoptosis; therefore, co-adminstraion of TRC102 is Caucasian 24 African American 6 Lymphocyte count decreased 6 5 anticipated to enhance the antitumor activity of temozolomide (TMZ), which methylates DNA Asian 2 Anemia 9 3 1 at N-7 and O-6 positions of guanine. Hispanic 2 Hypophosphatemia 2 2 Tumor Sites • We conducted a phase 1 trial of TRC102 in combination with TMZ to determine the safety, tolerability, GI 11 Fatigue 3 1 and maximum tolerated dose (MTD) of the combination (Clinicaltrials.gov identifier: NCT01851369) H&N 4 Hypophosphatemia 1 Lung 7 Hemolysis 1 1 1 • First enrollment: 7/16/2013.
    [Show full text]
  • In Patients with Metastatic Melanoma Nageatte Ibrahim1,2, Elizabeth I
    Cancer Medicine Open Access ORIGINAL RESEARCH A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma Nageatte Ibrahim1,2, Elizabeth I. Buchbinder1, Scott R. Granter3, Scott J. Rodig3, Anita Giobbie-Hurder4, Carla Becerra1, Argyro Tsiaras1, Evisa Gjini3, David E. Fisher5 & F. Stephen Hodi1 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 2Currently at Merck & Co.,, Kenilworth, New Jersey 3Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts 4Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 5Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts Keywords Abstract HDAC, immunotherapy, LBH589, melanoma, MITF, panobinostat Epigenetic alterations by histone/protein deacetylases (HDACs) are one of the many mechanisms that cancer cells use to alter gene expression and promote Correspondence growth. HDAC inhibitors have proven to be effective in the treatment of specific Elizabeth I. Buchbinder, Dana-Farber Cancer malignancies, particularly in combination with other anticancer agents. We con- Institute, 450 Brookline Avenue, Boston, ducted a phase I trial of panobinostat in patients with unresectable stage III or 02215, MA. Tel: 617 632 5055; IV melanoma. Patients were treated with oral panobinostat at a dose of 30 mg Fax: 617 632 6727; E-mail: [email protected] daily on Mondays, Wednesdays, and Fridays (Arm A). Three of the six patients on this dose experienced clinically significant thrombocytopenia requiring dose Funding Information interruption. Due to this, a second treatment arm was opened and the dose Novartis Pharmaceuticals Corporation was changed to 30 mg oral panobinostat three times a week every other week provided clinical trial support, additional (Arm B).
    [Show full text]
  • Refractory Multiple Myeloma Patients: a Meta-Analysis and Systematic Review
    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Arsenic trioxide-based therapy in relapsed/ refractory multiple myeloma patients: a meta-analysis and systematic review Xuepeng He Abstract: Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of Kai Yang malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. Peng Chen Although some newly approved drugs (thalidomide, lenalidomide, and bortezomib) demonstrate Bing Liu significant benefit for MM patients with improved survival, all MM patients still relapse. Arsenic Yuan Zhang trioxide (ATO) is the most active single agent in acute promyelocytic leukemia, the antitumor Fang Wang activity of which is partly dependent on the production of reactive oxygen species. Due to its multifaceted effects observed on MM cell lines and primary myeloma cells, Phase I/II trials have Zhi Guo been conducted in heavily pretreated patients with relapsed or refractory MM. Therapy regimens Xiaodong Liu varied dramatically as to the dosage of ATO and monotherapy versus combination therapy with Jinxing Lou For personal use only. other agents available for the treatment of MM. Although ATO-based combination treatment Huiren Chen was well tolerated by most patients, most trials found that ATO has limited effects on MM Department of Hematology, patients. However, since small numbers of patients were randomized to different treatment General Hospital of Beijing arms, trials have not been statistically powered to determine the differences in progression-free Military Area of PLA, Beijing, People’s Republic of China survival and overall survival among the experimental arms.
    [Show full text]
  • Maintenance Therapy in Solid Tumors Marie-Anne Smit, MD, MS,1 and John L
    Review Maintenance therapy in solid tumors Marie-Anne Smit, MD, MS,1 and John L. Marshall, MD2 1 Department of Internal Medicine, 2 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC The concept of maintenance therapy has been well studied in hematologic malignancies, and now, an increasing number of clinical trials explore the role of maintenance therapy in solid cancers. Both biological and lower-intensity chemotherapeutic agents are currently being evaluated as maintenance therapy. However, despite the increase in research in this area, there has not been consensus about the definition and timing of maintenance therapy. In this review, we will focus on continuation maintenance therapy and switch maintenance therapy in patients with metastatic solid tumors who have achieved stable disease, partial response, or complete response after first-line treatment. aintenance therapy is the subject of an apeutic agents, such as capecitabine and oral 5- increased interest in cancer research. fluorouracil (5-FU), are currently being evaluated as MIn contrast to conventional chemo- maintenance therapy. therapy that aims to kill as many cancer cells as Despite the increase in research in this area, possible, the goal of treatment with maintenance there is no consensus on the definition and timing therapy is to sustain a stable tumor mass, reduce of maintenance therapy. The term maintenance cancer-related symptoms, and prolong the time to therapy is used in a variety of treatment situations, progression and the related symptoms. A thera- such as prolonged first-line therapy and less- peutic strategy that is explicitly designed to main- intense or different therapy given after first-line tain a stable, tolerable tumor volume could in- therapy.
    [Show full text]
  • An Analysis of Toxicity and Response Outcomes from Dose
    Brock et al. BMC Cancer (2021) 21:777 https://doi.org/10.1186/s12885-021-08440-0 RESEARCH ARTICLE Open Access Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer Kristian Brock1* ,VictoriaHomer1, Gurjinder Soul2, Claire Potter1,CodyChiuzan3 and Shing Lee3 Abstract Background: The overwhelming majority of dose-escalation clinical trials use methods that seek a maximum tolerable dose, including rule-based methods like the 3+3, and model-based methods like CRM and EWOC. These methods assume that the incidences of efficacy and toxicity always increase as dose is increased. This assumption is widely accepted with cytotoxic therapies. In recent decades, however, the search for novel cancer treatments has broadened, increasingly focusing on inhibitors and antibodies. The rationale that higher doses are always associated with superior efficacy is less clear for these types of therapies. Methods: We extracted dose-level efficacy and toxicity outcomes from 115 manuscripts reporting dose-finding clinical trials in cancer between 2008 and 2014. We analysed the outcomes from each manuscript using flexible non-linear regression models to investigate the evidence supporting the monotonic efficacy and toxicity assumptions. Results: We found that the monotonic toxicity assumption was well-supported across most treatment classes and disease areas. In contrast, we found very little evidence supporting the monotonic efficacy assumption. Conclusions: Our conclusion is that dose-escalation trials routinely use methods whose assumptions are violated by the outcomes observed. As a consequence, dose-finding trials risk recommending unjustifiably high doses that may be harmful to patients. We recommend that trialists consider experimental designs that allow toxicity and efficacy outcomes to jointly determine the doses given to patients and recommended for further study.
    [Show full text]
  • Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver
    Vol. 9, 6343–6349, December 15, 2003 Clinical Cancer Research 6343 Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver H. Richard Alexander, Jr.,1 Steven K. Libutti,1 survival after disease progression is short. On the basis of a James F. Pingpank,1 Seth M. Steinberg,2 pattern of tumor progression predominantly in liver, con- David L. Bartlett,1 Cynthia Helsabeck,1 and tinued clinical evaluation of hepatic directed therapy in this patient population is justified. Tatiana Beresneva1 1Surgical Metabolism Section, Surgery Branch, Center for Cancer Research and 2Biostatistics and Data Management Section, Center for INTRODUCTION Cancer Research, National Cancer Institute, Bethesda, Maryland There are ϳ54,200 new cases of malignant melanoma diagnosed annually in the United States (1), of which 3–6% are ABSTRACT primary ocular melanoma representing up to 4,000 new cases/ Purpose: Liver metastases are the sole or life-limiting year (2). Metastatic disease occurs in 40–60% of patients with component of disease in the majority of patients with ocular ocular melanoma (3), and unresectable hepatic metastases rep- melanoma who recur. Because median survival after diag- resent the life-limiting component of progressive disease in nosis of liver metastases is short and no satisfactory treat- ϳ80% of patients with ocular melanoma in this setting (3–5). ment options exist, we have conducted clinical trials evalu- Even with aggressive treatment, the median survival after liver ating isolated hepatic perfusion (IHP) for patients afflicted metastases from ocular melanoma are diagnosed is between 2 with this condition. and 7 months and 1-year survival is ϳ10% (5).
    [Show full text]
  • Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant
    Author Manuscript Published OnlineFirst on April 1, 2020; DOI: 10.1158/1541-7786.MCR-19-0669 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Targeting NAD+ biosynthesis overcomes panobinostat and bortezomib-induced malignant glioma resistance Esther P. Jane, 1, 2 Daniel R. Premkumar, 1, 2, 3 Swetha Thambireddy, 1 Brian Golbourn, 1 Sameer Agnihotri, 1, 2, 3 Kelsey C. Bertrand, 4 Stephen C. Mack, 4 Max I. Myers, 1 Ansuman Chattopadhyay, 5 D. Lansing Taylor, 6, 7, 8 Mark E. Schurdak, 6, 7, 8 Andrew M. Stern, 7, 8 and Ian F. Pollack 1, 2, 3 Department of Neurosurgery 1, University of Pittsburgh School of Medicine 2, University of Pittsburgh Cancer Institute Brain Tumor Center 3, Texas Children's Hospital, Baylor College of Medicine 4, University of Pittsburgh Molecular Biology Information Service 5, University of Pittsburgh Cancer Institute 6, University of Pittsburgh Drug Discovery Institute 7, Department of Computational and Systems Biology, University of Pittsburgh School of Medicine 8, Pittsburgh, Pennsylvania, U.S.A. Disclosure of Potential Conflict of Interest The authors have declared that no conflict of interest exists. 1 Downloaded from mcr.aacrjournals.org on October 2, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 1, 2020; DOI: 10.1158/1541-7786.MCR-19-0669 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Keywords: Panobinostat, bortezomib, synergy, resistance, glioma,
    [Show full text]
  • The Synergic Antitumor Effects of Paclitaxel and Temozolomide Co-Loaded in Mpeg-PLGA Nanoparticles on Glioblastoma Cells
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 15 The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells Yuanyuan Xu1,*, Ming Shen1,*, Yiming Li2, Ying Sun1, Yanwei Teng1, Yi Wang2, Yourong Duan1 1 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200032, P. R. China 2Department of Ultrasound, Huashan Hospital, School of Medicine, Fudan University, Shanghai 200040, P. R. China *These authors have contributed equally to this work Correspondence to: Yourong Duan, e-mail: [email protected] Yi Wang, e-mail: [email protected] Keywords: nanoparticles, synergy, glioblastoma, paclitaxel, temozolomide Received: November 12, 2015 Accepted: February 20, 2016 Published: March 03, 2016 ABSTRACT To get better chemotherapy efficacy, the optimal synergic effect of Paclitaxel (PTX) and Temozolomide (TMZ) on glioblastoma cells lines was investigated. A dual drug-loaded delivery system based on mPEG-PLGA nanoparticles (NPs) was developed to potentiate chemotherapy efficacy for glioblastoma. PTX/TMZ-NPs were prepared with double emulsification solvent evaporation method and exhibited a relatively uniform diameter of 206.3 ± 14.7 nm. The NPs showed sustained release character. Cytotoxicity assays showed the best synergistic effects were achieved when the weight ratios of PTX to TMZ were 1:5 and 1:100 on U87 and C6 cells, respectively. PTX/TMZ-NPs showed better inhibition effect to U87 and C6 cells than single drug NPs or free drugs mixture. PTX/TMZ-NPs (PTX: TMZ was 1:5(w/w)) significantly inhibited the tumor growth in the subcutaneous U87 mice model.
    [Show full text]